Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Y Kim

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
JAMA Network Open|January 15, 2025
Insights Into Opportunistic Lung Cancer Screening for Individuals Who Have Never SmokedRoger Y Kim
Cancer Biomarkers : Section a of Disease Markers|March 1, 2024
Radiomics and artificial intelligence for risk stratification of pulmonary nodules: Ready for primetime?Roger Y Kim
Chest|September 11, 2025
The Association of Lung Cancer Screening Centralization With Annual Adherence RatesRoger Y Kim
Current Opinion in Pulmonary Medicine|February 6, 2026
Improving lung cancer screening diagnostic efficiencyChristopher R Caruso, Roger Y Kim
Journal of the American College of Radiology : JACR|December 3, 2025
Monitoring the Harms of Lung Cancer Screening: Why the Nonmalignant Resection Rate Is Our Best BetChristopher R Caruso, Anil Vachani, Roger Y Kim
CHEST Pulmonary|April 30, 2025
Rebuttal From Dr Kim et alRoger Y Kim, Catherine R Sears, Nicholas J Pastis
CHEST Pulmonary|April 30, 2025
Liquid Markers for Risk Stratification of Pulmonary Nodules, Ready for Prime Time? Yes!Roger Y Kim, Catherine R Sears, Nicholas J Pastis
Seminars in Respiratory and Critical Care Medicine|September 17, 2019
Malignant Mesothelioma: Has Anything Changed?Roger Y Kim, Daniel H Sterman, Andrew R Haas
The American Journal of Medicine|August 1, 2020
Recanalization of Complete Airway Stenosis After Blunt Force Chest TraumaRoger Y Kim, Kevin C Ma, Andrew R Haas
Lung Cancer (Amsterdam, Netherlands)|July 28, 2021
Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesotheliomaRoger Y Kim, Yimei Li, Melina E Marmarelis, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
JAMA Network Open|January 15, 2025
Insights Into Opportunistic Lung Cancer Screening for Individuals Who Have Never SmokedRoger Y Kim
Cancer Biomarkers : Section a of Disease Markers|March 1, 2024
Radiomics and artificial intelligence for risk stratification of pulmonary nodules: Ready for primetime?Roger Y Kim
Chest|September 11, 2025
The Association of Lung Cancer Screening Centralization With Annual Adherence RatesRoger Y Kim
Current Opinion in Pulmonary Medicine|February 6, 2026
Improving lung cancer screening diagnostic efficiencyChristopher R Caruso, Roger Y Kim
Journal of the American College of Radiology : JACR|December 3, 2025
Monitoring the Harms of Lung Cancer Screening: Why the Nonmalignant Resection Rate Is Our Best BetChristopher R Caruso, Anil Vachani, Roger Y Kim
CHEST Pulmonary|April 30, 2025
Rebuttal From Dr Kim et alRoger Y Kim, Catherine R Sears, Nicholas J Pastis
CHEST Pulmonary|April 30, 2025
Liquid Markers for Risk Stratification of Pulmonary Nodules, Ready for Prime Time? Yes!Roger Y Kim, Catherine R Sears, Nicholas J Pastis
Seminars in Respiratory and Critical Care Medicine|September 17, 2019
Malignant Mesothelioma: Has Anything Changed?Roger Y Kim, Daniel H Sterman, Andrew R Haas
The American Journal of Medicine|August 1, 2020
Recanalization of Complete Airway Stenosis After Blunt Force Chest TraumaRoger Y Kim, Kevin C Ma, Andrew R Haas
Lung Cancer (Amsterdam, Netherlands)|July 28, 2021
Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesotheliomaRoger Y Kim, Yimei Li, Melina E Marmarelis, et al.
Pageof 4